Peptides for growth hormone and body composition, ranked by human evidence

Peptides that act on the growth-hormone axis, studied for muscle, fat and recovery — including approved growth-hormone and secretagogue medicines and many research peptides. They are ranked by an evidence score that weighs the grade of the evidence, the human trials counted in PubMed, and regulatory status — shown in the columns so any rank can be checked. A high score means a peptide is well studied and often approved for something, not that it is right, safe or legal for this goal. Nothing here is medical advice, and Grey Peptides sells nothing and links to no vendor. See all goals or the plainer browse by goal map.

Evidence grade

Regulatory status

Search name

Has a human trial on this page

43 peptides · sorted by evidence score (click a column to re-sort)

Peptide	Grade	Human studies	RCTs	Max trial phase	Regulatory	Dose	Score
Thyrotropin alfa	High	800	48	Phase 4	FDA approved	intramuscular →	100
Tesamorelin	High	107	26	Phase 4	FDA approved	—	100
Vosoritide	High	89	7	Phase 3	FDA approved	subcutaneous →	100
Somapacitan	High	65	23	Phase 3	FDA approved	subcutaneous →	100
Somatrogon	High	54	12	Phase 3	FDA approved	subcutaneous →	100
Lonapegsomatropin	High	35	6	Phase 3	FDA approved	subcutaneous →	100
Macimorelin	High	32	7	Phase 3	FDA approved	oral →	100
Navepegritide	High	9	4	Phase 3	FDA approved	—	100
IGF-1	High	37,304	2,408	Phase 4	FDA approved	subcutaneous →	90
Corticotropin	High	35,809	1,271	Phase 4	FDA approved	intramuscular or subcutaneous →	90
HCG	High	35,572	1,422	Phase 4	FDA approved	sourced dose →	90
Mecasermin	High	26,676	1,849	Phase 3	FDA approved	subcutaneous →	90
Somatostatin	High	24,896	1,176	Phase 4	Approved abroad	—	90
Octreotide	High	10,156	541	Phase 4	FDA approved	subcutaneous or intravenous →	90
Corticorelin	High	8,178	298	Phase 4	FDA approved	intravenous bolus →	90
Somatropin (HGH)	High	7,503	590	Phase 4	FDA approved	—	90
Tetracosactide	High	2,086	162	Phase 4	FDA approved	intravenous or intramuscular →	90
Lanreotide	High	1,202	92	Phase 4	FDA approved	—	90
Pasireotide	High	679	55	Phase 4	FDA approved	subcutaneous →	90
Pegvisomant	High	624	39	Phase 4	FDA approved	subcutaneous →	90
Capromorelin	High	22	4	—	Veterinary	—	85
Anamorelin	High	135	12	Phase 3	Approved abroad	oral →	80
Protirelin	High	9,961	267	Phase 3	Discontinued	—	75
Growth hormone-releasing hormone	Medium	3,412	285	Phase 4	Research only	intravenous →	65
Somatrem	Medium	94	11	—	Discontinued	injection →	65
Ipamorelin	Medium	29	2	Phase 2	Research only	—	65
CJC-1295	Medium	25	1	Phase 2	Research only	—	65
GHRP-2	Medium	161	43	—	Approved abroad	intravenous →	60
Ghrelin	Medium	11,055	1,685	Phase 4	Research only	—	55
Mecasermin rinfabate	Medium	623	21	Phase 4	Discontinued	—	55
GHRP-6	Medium	323	25	—	Research only	—	55
Sermorelin	Medium	291	38	Phase 4	Discontinued	—	55
Hexarelin	Medium	193	27	—	Research only	—	55
MK-677	Medium	105	19	Phase 3	Research only	oral →	55
Beta-lipotropin	Low	552	16	Phase 4	Research only	—	45
Cortistatin	Low	194	5	Phase 4	Research only	—	45
GHRP-1	Low	24	3	Phase 2	Research only	—	35
Alexamorelin	Low	8	0	—	Research only	intravenous →	35
Sometribove	Low	0	13	—	Veterinary	—	30
GHRP-4	Low	6	0	—	Research only	—	25
GHRP-5	Low	6	0	—	Research only	—	25
CJC-1293	Low	3	0	—	Research only	—	25
Mod GRF 1-29	Low	0	0	—	Research only	—	20

Other goals: Weight loss and metabolism · Healing, injury and recovery · Skin and hair · Focus, mood and the brain · Heart and circulation · Sexual and reproductive health · Longevity and cell health · Immune defence and infection · Diagnostic and research tools · In development

How the evidence score works

Evidence score (0-100), a transparent ranking aid, not a verdict. grade: high=60, medium=40, low=20, ungraded=0. Human trial: an on-site read-and-cited randomized or clinical trial = +15, else any PubMed human-indexed record = +5, else 0. RCT literature: PubMed lists >=1 randomized controlled trial = +10. Regulatory: FDA-approved = +15, in trials / approved-abroad / in development = +5, else 0. Every component is stored on each record so the number can be re-derived; volume and grade are shown together so neither misleads.

“Human studies” and “RCTs” are PubMed record counts for the peptide (read 2026-11-07 from the counts behind the Evidence Explorer); a count is how much research exists and of what kind, never proof a peptide works. “Grade” is our editorial reading of the evidence — see how we grade evidence. The “Dose” column links to the entry for each peptide that carries a dose from a regulator’s label or a published human study — where the amount is shown with its source; the amount is never reprinted here without that source, and many research peptides have no human dose, shown as —. Of 660 peptides, 607 have at least one human-indexed PubMed record, 324 cite a human trial on their page, 124 are FDA-approved, and 271 carry a sourced dose.